Approximately 70% of new drug candidates fall into Class II of the Biopharmaceutical Classification System (BCS), indicating poor bioavailability due to low solubility. To increase the bioavailability of this class of compounds, formulators are increasingly turning to amorphous spray-dried dispersions. Kim Shepard at Lonza discusses how secondary drying is the finishing touch in manufacturing.